These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations. di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118 [TBL] [Abstract][Full Text] [Related]
31. The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib. Kobialka P; Sabata H; Vilalta O; Gouveia L; Angulo-Urarte A; Muixí L; Zanoncello J; Muñoz-Aznar O; Olaciregui NG; Fanlo L; Esteve-Codina A; Lavarino C; Javierre BM; Celis V; Rovira C; López-Fernández S; Baselga E; Mora J; Castillo SD; Graupera M EMBO Mol Med; 2022 Jul; 14(7):e15619. PubMed ID: 35695059 [TBL] [Abstract][Full Text] [Related]
32. Somatic mutations in exon 17 of the TEK gene in vascular tumors and vascular malformations. Ye C; Pan L; Huang Y; Ye R; Han A; Li S; Li X; Wang S J Vasc Surg; 2011 Dec; 54(6):1760-8. PubMed ID: 21962923 [TBL] [Abstract][Full Text] [Related]
33. Repurposing alpelisib, an anti-cancer drug, for the treatment of severe TIE2-mutated venous malformations: Preliminary pharmacokinetics and pharmacodynamic data. Remy A; Tran TH; Dubois J; Gavra P; Lapointe C; Winikoff R; Facundo GB; Théorêt Y; Kleiber N Pediatr Blood Cancer; 2022 Oct; 69(10):e29897. PubMed ID: 35876545 [TBL] [Abstract][Full Text] [Related]
34. Cerebrofacial vascular metameric syndrome is caused by somatic pathogenic variants in Sheppard SE; Sanders VR; Srinivasan A; Finn LS; Adams D; Elton A; Amlie-Lefond C; Nelson Z; Dmyterko V; Jensen D; Zenner K; Perkins J; Bennett JT Cold Spring Harb Mol Case Stud; 2021 Dec; 7(6):. PubMed ID: 34887309 [TBL] [Abstract][Full Text] [Related]
36. Microphysiological model of PIK3CA-driven vascular malformations reveals a role of dysregulated Rac1 and mTORC1/2 in lesion formation. Aw WY; Cho C; Wang H; Cooper AH; Doherty EL; Rocco D; Huang SA; Kubik S; Whitworth CP; Armstrong R; Hickey AJ; Griffith B; Kutys ML; Blatt J; Polacheck WJ Sci Adv; 2023 Feb; 9(7):eade8939. PubMed ID: 36791204 [TBL] [Abstract][Full Text] [Related]
37. Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum. Garreta Fontelles G; Pardo Pastor J; Grande Moreillo C Br J Clin Pharmacol; 2022 Aug; 88(8):3891-3895. PubMed ID: 35146800 [TBL] [Abstract][Full Text] [Related]
39. Progressive vascular tumor in infant: A case report and literature review of PIK3CA vascular malformation. Medina A; Zima L; Atkinson A; Menon NM; Bhattacharjee M; Bonfante E; Sandberg DI; Greives MR; Shah M Childs Nerv Syst; 2024 Apr; 40(4):1005-1010. PubMed ID: 38265477 [TBL] [Abstract][Full Text] [Related]
40. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]